Heart failure & cardiomyopathies
Evaluating deceleration and acceleration capacities: Implications for predicting adverse outcomes in patients with hypertrophic cardiomyopathy
Authors' conclusion
DC and AC are independent predictors of the high mortality risk in patients with HCM, suggesting their clinical utility as electrophysiological markers for identifying high-risk individuals in this population.
Study context
- Population
- Unrelated patients with hypertrophic cardiomyopathy (HCM), enrolled between 2013 and 2022unrelated patients with HCM enrolled
- Participants
- 856 patients
- Exposure
- Associations of deceleration capacity (DC) and acceleration capacity (AC) with clinical outcomes
- Outcome
- All-cause death
- Follow-up
- Median 3.0 years (interquartile range: 2.3-3.9)
Main finding
As reported in the abstract
Estimate (CI)P value
Lower values of DCunadjusted; lower DC associated with higher risk
HR 1.391(1.131–1.712)
P = 0.002Lower values of DCafter adjustment
adjusted HR 1.330(1.072–1.650)
P = 0.010ACAC predicted higher risk
HR 1.458(1.195–1.779)
P < 0.001ACafter adjustment
adjusted HR 1.391(1.133–1.709)
P = 0.002- Cases of all-cause death
- 25
Observational data: associations, not effects.
Secondary outcomes
Cardiovascular death (secondary outcome) · median follow-up of 3.0 years (interquartile range: 2.3-3.9)
| HR (CI) | P value | ||
|---|---|---|---|
| Lower values of DCUnadjusted; lower DC associated with higher risk | 1.311 (1.017–1.689) | P = 0.036 | |
| ACAs printed; AC predicted higher risk | 0.404 (1.104–1.789) | P = 0.006 | |
| 0.512Hazard ratio (log scale) |
- Cardiovascular death (secondary outcome) — Cases of cardiovascular death
- 17
Original publication
Evaluating deceleration and acceleration capacities: Implications for predicting adverse outcomes in patients with hypertrophic cardiomyopathy. Heart Rhythm. Published 3 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →